FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced that FUJIFILM Irvine Scientific, Inc., a world leader in the development and manufacture of serum-free and chemically defined cell culture media for life science research, bioproduction, and cell therapy manufacturing, will acquire Shenandoah Biotechnology, Inc., a leading manufacturer of recombinant proteins.
Shenandoah Biotechnology is a privately held company located in Warminster, Pennsylvania, that manufactures recombinant proteins including cytokines and growth factors. Shenandoah Biotechnology recently launched their CTG Grade™ line of cytokines and growth factors that are manufactured according to cGMP guidelines in the Company’s new state-of-the-art, ISO 9001:2015 certified facility.
The use of cGMP manufactured products smooths the transition of biological therapies from preclinical to clinical phases.
“At Fujifilm, our goal has always been to bring new value to society through the creation of innovative technologies, products and services,” said Teiichi Goto, president and chief executive officer, representative director of FUJIFILM Corporation. “The acquisition of Shenandoah Biotechnology marks an important milestone for us to establish a leading position as a partner for pharmaceutical customers in the rapidly-growing market of advanced therapy. Fujifilm will, by maximizing our group synergy, continue to expand Life Sciences Business while contributing to the creation of new therapies that fulfill unmet medical needs.”
“FUJIFILM Irvine Scientific is committed to helping customers bring advanced therapies to market faster, and to use innovation to make therapies more accessible,” said Yutaka Yamaguchi, chairman and chief executive officer, FUJIFILM Irvine Scientific. “Shenandoah Biotechnology’s portfolio of recombinant proteins complement our advanced cell culture solutions and expertise in bioprocessing, providing our collective customers a single point of access for their life science research, discovery, and cell and gene therapy needs. This acquisition will be an important step toward achieving sales target of 100 billion yen (about 850 million USD*) in Fujifilm’s Life Sciences Business by FY2025.”
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox!
Sign up now!